The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AGN-PC-00EU2P     4-(3,4-dichlorophenyl)-N- methyl-1,2,3,4...

Synonyms: SureCN137619, AC-740, AG-A-66112, MolMap_000056, ANW-58148, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of sertraline


Psychiatry related information on sertraline


High impact information on sertraline


Chemical compound and disease context of sertraline


Biological context of sertraline

  • METHOD: Patients who met symptom criteria and reported impaired functioning after three screening cycles were randomly assigned to three cycles of double-blind, placebo-controlled treatment with continuous (full-cycle dosing) or intermittent (luteal-phase dosing) sertraline [19].
  • RESULTS: The safety profiles of the two treatments were similar except that nortriptyline treatment was associated with a significant increase in pulse rate, whereas sertraline was associated with a nonsignificant decrease [20].
  • METHOD: The extent of maternal and infant transporter blockade was assessed by measurement of platelet levels of 5-HT in 14 breast-feeding mother-infant pairs before and after 6-16 weeks of maternal treatment with sertraline for major depression with postpartum onset [21].
  • OBJECTIVE: The authors' goal was to determine whether sertraline attenuates the increased platelet activation seen among depressed patients [22].
  • Prolonged bleeding time in a patient treated with sertraline [23].

Anatomical context of sertraline


Associations of sertraline with other chemical compounds

  • CONCLUSIONS: The SRI sertraline was more effective in reducing MDD and OCD symptoms than the primarily norepinephrine reuptake inhibitor desipramine for patients with concurrent OCD and MDD [27].
  • We show that some antihistaminic compounds (hydroxyzine and promethazine) and other pharmacological compounds with a related structure (including thioridazine and sertraline) kill tumor cells and significantly decrease the level of TCTP [28].
  • Chronic (21 d), but not acute (1 d), administration of several different antidepressant drugs, including tranylcypromine, sertraline, desipramine, or mianserin, significantly increased BDNF mRNA and all but mianserin increased trkB mRNA in hippocampus [29].
  • RESULTS: Sertraline and desmethylsertraline were present in all breast milk samples, with a gradient from "fore" milk to "hind" milk [30].
  • METHODS: One hundred fifty-six men and women with MDD (age, > or = 50 years) were assigned randomly to a program of aerobic exercise, antidepressants (sertraline hydrochloride), or combined exercise and medication [31].

Gene context of sertraline

  • Clinical investigations (with desipramine) confirmed in vitro findings that CYP2D6 inhibition by sertraline is only moderate [32].
  • These results suggest that sertraline at the maximum recommended dosage under steady-state conditions, and demethylsertraline, the principal metabolite of sertraline, are unlikely to exert significant inhibitory effects on the CYP2C19 and CYP3A3/4 hepatic isoenzymes responsible for the metabolism of diazepam [33].
  • The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline [34].
  • All three antidepressants significantly reduced IFN gamma secretion, whereas clomipramine and sertraline significantly increased IL-10 secretion in culture supernatant [35].
  • The observations reported here suggest that fluoxetine and sertraline would have little effect on CYP3A-mediated clearance of coadministered drugs [36].

Analytical, diagnostic and therapeutic context of sertraline


  1. Sertraline and hyponatremia. Kessler, J., Samuels, S.C. N. Engl. J. Med. (1996) [Pubmed]
  2. Elevated serum thyrotropin in thyroxine-treated patients with hypothyroidism given sertraline. McCowen, K.C., Garber, J.R., Spark, R. N. Engl. J. Med. (1997) [Pubmed]
  3. Sertraline treatment of major depression in patients with acute MI or unstable angina. Glassman, A.H., O'Connor, C.M., Califf, R.M., Swedberg, K., Schwartz, P., Bigger, J.T., Krishnan, K.R., van Zyl, L.T., Swenson, J.R., Finkel, M.S., Landau, C., Shapiro, P.A., Pepine, C.J., Mardekian, J., Harrison, W.M., Barton, D., Mclvor, M. JAMA (2002) [Pubmed]
  4. Sudden chest pain with sertraline. Berti, C.A., Doogan, D.P. Lancet (1994) [Pubmed]
  5. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. Brady, K., Pearlstein, T., Asnis, G.M., Baker, D., Rothbaum, B., Sikes, C.R., Farfel, G.M. JAMA (2000) [Pubmed]
  6. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. March, J.S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E.H., Cutler, N.R., Dominguez, R., Ferguson, J., Muller, B., Riesenberg, R., Rosenthal, M., Sallee, F.R., Wagner, K.D., Steiner, H. JAMA (1998) [Pubmed]
  7. Relapse of depressive symptoms after discontinuing sertraline. Baldessarini, R.J., Viguera, A.C. JAMA (1999) [Pubmed]
  8. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Pollack, M.H., Otto, M.W., Worthington, J.J., Manfro, G.G., Wolkow, R. Arch. Gen. Psychiatry (1998) [Pubmed]
  9. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Lyketsos, C.G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C.D., Munro, C., Baker, A.S., Sheppard, J.M., Frangakis, C., Brandt, J., Rabins, P.V. Arch. Gen. Psychiatry (2003) [Pubmed]
  10. Sertraline and breast-feeding. Epperson, C.N., Anderson, G.M., McDougle, C.J. N. Engl. J. Med. (1997) [Pubmed]
  11. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Kroenke, K., West, S.L., Swindle, R., Gilsenan, A., Eckert, G.J., Dolor, R., Stang, P., Zhou, X.H., Hays, R., Weinberger, M. JAMA (2001) [Pubmed]
  12. Exacerbations of neurally mediated syncope associated with sertraline. Tandan, T., Giuffre, M., Sheldon, R. Lancet (1997) [Pubmed]
  13. Sertraline and platelet counts in idiopathic thrombocytopenia purpura. Krivy, J., Wiener, J. Lancet (1995) [Pubmed]
  14. Sertraline for Prevention of Depression Recurrence in Diabetes Mellitus: A Randomized, Double-blind, Placebo-Controlled Trial. Lustman, P.J., Clouse, R.E., Nix, B.D., Freedland, K.E., Rubin, E.H., McGill, J.B., Williams, M.M., Gelenberg, A.J., Ciechanowski, P.S., Hirsch, I.B. Arch. Gen. Psychiatry (2006) [Pubmed]
  15. Early coadministration of clonazepam with sertraline for panic disorder. Goddard, A.W., Brouette, T., Almai, A., Jetty, P., Woods, S.W., Charney, D. Arch. Gen. Psychiatry (2001) [Pubmed]
  16. SIADH associated with fluoxetine and sertraline therapy. Jackson, C., Carson, W., Markowitz, J., Mintzer, J. The American journal of psychiatry. (1995) [Pubmed]
  17. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Leverich, G.S., Altshuler, L.L., Frye, M.A., Suppes, T., McElroy, S.L., Keck, P.E., Kupka, R.W., Denicoff, K.D., Nolen, W.A., Grunze, H., Martinez, M.I., Post, R.M. The American journal of psychiatry. (2006) [Pubmed]
  18. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. Grubb, B.P., Samoil, D., Kosinski, D., Kip, K., Brewster, P. J. Am. Coll. Cardiol. (1994) [Pubmed]
  19. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Freeman, E.W., Rickels, K., Sondheimer, S.J., Polansky, M., Xiao, S. The American journal of psychiatry. (2004) [Pubmed]
  20. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Bondareff, W., Alpert, M., Friedhoff, A.J., Richter, E.M., Clary, C.M., Batzar, E. The American journal of psychiatry. (2000) [Pubmed]
  21. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Epperson, N., Czarkowski, K.A., Ward-O'Brien, D., Weiss, E., Gueorguieva, R., Jatlow, P., Anderson, G.M. The American journal of psychiatry. (2001) [Pubmed]
  22. Platelet activation in depression and effects of sertraline treatment: An open-label study. Markovitz, J.H., Shuster, J.L., Chitwood, W.S., May, R.S., Tolbert, L.C. The American journal of psychiatry. (2000) [Pubmed]
  23. Prolonged bleeding time in a patient treated with sertraline. Calhoun, J.W., Calhoun, D.D. The American journal of psychiatry. (1996) [Pubmed]
  24. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. Benmansour, S., Cecchi, M., Morilak, D.A., Gerhardt, G.A., Javors, M.A., Gould, G.G., Frazer, A. J. Neurosci. (1999) [Pubmed]
  25. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Salomon, R.M., Ripley, B., Kennedy, J.S., Johnson, B., Schmidt, D., Zeitzer, J.M., Nishino, S., Mignot, E. Biol. Psychiatry (2003) [Pubmed]
  26. Effect of sertraline on regional metabolic rate in patients with affective disorder. Buchsbaum, M.S., Wu, J., Siegel, B.V., Hackett, E., Trenary, M., Abel, L., Reynolds, C. Biol. Psychiatry (1997) [Pubmed]
  27. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Hoehn-Saric, R., Ninan, P., Black, D.W., Stahl, S., Greist, J.H., Lydiard, B., McElroy, S., Zajecka, J., Chapman, D., Clary, C., Harrison, W. Arch. Gen. Psychiatry (2000) [Pubmed]
  28. Translationally controlled tumor protein is a target of tumor reversion. Tuynder, M., Fiucci, G., Prieur, S., Lespagnol, A., Géant, A., Beaucourt, S., Duflaut, D., Besse, S., Susini, L., Cavarelli, J., Moras, D., Amson, R., Telerman, A. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  29. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Nibuya, M., Morinobu, S., Duman, R.S. J. Neurosci. (1995) [Pubmed]
  30. Sertraline and desmethylsertraline in human breast milk and nursing infants. Stowe, Z.N., Owens, M.J., Landry, J.C., Kilts, C.D., Ely, T., Llewellyn, A., Nemeroff, C.B. The American journal of psychiatry. (1997) [Pubmed]
  31. Effects of exercise training on older patients with major depression. Blumenthal, J.A., Babyak, M.A., Moore, K.A., Craighead, W.E., Herman, S., Khatri, P., Waugh, R., Napolitano, M.A., Forman, L.M., Appelbaum, M., Doraiswamy, P.M., Krishnan, K.R. Arch. Intern. Med. (1999) [Pubmed]
  32. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann, P. Clinical pharmacokinetics. (1996) [Pubmed]
  33. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Gardner, M.J., Baris, B.A., Wilner, K.D., Preskorn, S.H. Clinical pharmacokinetics. (1997) [Pubmed]
  34. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. Ozdemir, V., Naranjo, C.A., Herrmann, N., Shulman, R.W., Sellers, E.M., Reed, K., Kalow, W. Journal of clinical psychopharmacology. (1998) [Pubmed]
  35. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Maes, M., Song, C., Lin, A.H., Bonaccorso, S., Kenis, G., De Jongh, R., Bosmans, E., Scharpé, S. Neuropsychopharmacology (1999) [Pubmed]
  36. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. Ring, B.J., Binkley, S.N., Roskos, L., Wrighton, S.A. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  37. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Thase, M.E., Fava, M., Halbreich, U., Kocsis, J.H., Koran, L., Davidson, J., Rosenbaum, J., Harrison, W. Arch. Gen. Psychiatry (1996) [Pubmed]
  38. Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Glassman, A.H., Bigger, J.T., Gaffney, M., Shapiro, P.A., Swenson, J.R. Arch. Gen. Psychiatry (2006) [Pubmed]
  39. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Katzelnick, D.J., Kobak, K.A., Greist, J.H., Jefferson, J.W., Mantle, J.M., Serlin, R.C. The American journal of psychiatry. (1995) [Pubmed]
  40. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Van Ameringen , M.A., Lane, R.M., Walker, J.R., Bowen, R.C., Chokka, P.R., Goldner, E.M., Johnston, D.G., Lavallee, Y.J., Nandy, S., Pecknold, J.C., Hadrava, V., Swinson, R.P. The American journal of psychiatry. (2001) [Pubmed]
WikiGenes - Universities